Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new Medium article from our Department explores how optogenetics has transformed neuroscientific research and opened new possibilities for the treatment of brain disorders, and sheds light on the series of early research work undertaken by Professor Gero Miesenböck and his team to evolve this breakthrough technology.

Image: Gero Miesenböck

On the afternoon of 12 June 1999, a Saturday, Gero Miesenböck returned to his apartment in Manhattan from a long walk after lunch, ready to open a book he had been absorbed in, Independence Day by Richard Ford. “As I was reaching for the book, drifting from the real world into Ford’s fictional New Jersey, there was the idea of optogenetic control. I knew instantly that I was on to something. My wife remembers my excitement as I tried to explain the concept to her, and especially the terrible hangover nearly two years later when my postdoc and I celebrated that we had got it to work.”

That Manhattan moment launched a series of now classical studies that made Miesenböck the first scientist to modify nerve cells genetically so that their activity could be controlled by light. This breakthrough technology, called optogenetics, has transformed neuroscientific research and opened new possibilities for the treatment of brain disorders. By providing the means to control neural signals with high precision, optogenetics has raised neurobiology’s standards of proof. It has shed light, literally and figuratively, on virtually every brain function: sensation and movement, motivation and learning, sleep and waking, communication and decision-making.

Read more (Medium website)

Similar stories

Drug trial that could improve respiratory recovery from COVID-19 now underway

Research

A clinical trial has commenced this week to test whether a drug called almitrine can help people who are seriously ill with COVID-19 to recover from the disease.

Same genome, different worlds: How a similar brain causes sexually dimorphic behaviours

CNCB Goodwin Group News Publication Research

A new paper from the Goodwin group based in DPAG's Centre for Neural Circuits and Behaviour has shown how males and females are programmed differently in terms of sex.

New form of gift wrap drives male reproductive success

Publication Research Wilson Group News

The transfer of complex mixtures of signals and nutrients between individuals is a key step in several biologically important events in our lives, such as breastfeeding and sexual intercourse. However, we know relatively little about the ways in which the molecular gifts involved are packaged to ensure their successful delivery to the recipient.

Just over half of British Indians would take COVID vaccine

EDI News Outreach Postdoctoral Publication Research Riley Group News

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Earliest origins of the forming heart identified

Cardiac Theme Postdoctoral Publication Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.